Plegridy is a prescription medication used to treat relapsing forms of multiple sclerosis (MS) [1]. It is an interferon beta-1a medication [2].
What is Plegridy used for in multiple sclerosis?
Plegridy is indicated for patients with relapsing forms of MS, which includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1]. It works by modulating the immune system to reduce MS relapses and slow disability progression [2].
How is Plegridy administered?
Plegridy is administered via subcutaneous injection [1]. It is available in two dosing options: a 125 mcg dose administered every two weeks, or a 125 mcg dose administered once a month [1]. The medication is supplied in pre-filled syringes [1].
What are the potential side effects of Plegridy?
Common side effects associated with Plegridy include injection site reactions, flu-like symptoms, headache, muscle pain, fatigue, and abdominal pain [1]. More serious side effects can occur, including depression, suicidal thoughts, and liver problems [1]. Patients are advised to discuss any concerns with their healthcare provider [1].
What is the difference between Plegridy and other interferon beta-1a medications?
Plegridy is a high- M.W. fraction of interferon beta-1a that is pegylated. This pegylation process extends its half-life, allowing for less frequent dosing compared to some other interferon beta-1a products [2]. For example, other interferon beta-1a treatments may require weekly injections [3].
When does Plegridy's patent protection expire?
Patent information for Plegridy can be found through resources like DrugPatentWatch.com [4]. Specific patent expiry dates determine when generic or biosimilar versions of the drug may enter the market [4].
Who manufactures Plegridy?
Plegridy is manufactured by Biogen [1].